42
Podcast

Why Most Medtech Fundraisers Fail and What to Do Instead - Kiko Filipov, Partner at APPARIUS

Raising capital in Medtech is tougher than ever. Investor expectations have shifted. Competition is up. And many founders are still pitching like it’s 2018. In this episode, Henry Norton sits down with Kiko Filipov, Partner at APPARIUS Corporate Finance and Strategic Advisor at Cruxx, to unpack the real mechanics of a successful fundraise in 2025. From first-in-human data to commercial readiness, Kiko shares what separates the rounds that get oversubscribed from the ones that stall. He also explores the changing landscape of Medtech innovation and why strategic exits take years of planning, how emerging markets are joining the race, and where VCs are placing bets across surgical robotics, neurostimulation, and digital health. Whether you're gearing up for Series A or preparing your pitch deck, this episode delivers tactical clarity from someone who’s in the room with both founders and funds.

Why Most Medtech Fundraisers Fail and What to Do Instead - Kiko Filipov, Partner at APPARIUS

ALSO AVAILABLE ON

SpotifyApple podcastsAmazon music
Share
Why Most Medtech Fundraisers Fail and What to Do Instead

Kiko Filipov, Partner at APPARIUS

Fundraising and M&A in MedTech: Lessons from the Frontline with Kiko Filipov

Raising capital in medtech has never been easy—but in 2025, it’s harder than ever.
On Episode 8 of The Crux of MedTech Podcast, we sat down with Kiko Filipov, Partner at Apparius Corporate Finance and strategic advisor to Cruxx, to explore why so many startups are struggling to raise—and what separates the winners from the rest.

Why MedTech Fundraises Fail in 2025

There’s no shortage of innovation. But too many founders focus on tech, not the equity story.
Kiko highlighted several recurring issues:

  • Lack of reimbursement strategy – Investors need confidence in ROI. A killer indication without clarity on reimbursement won’t fly.

  • Weak commercial planning – Even at pre-Series A, you need a vision for market entry and sales infrastructure.

  • Spray-and-pray outreach – Sending your deck to every VC on LinkedIn? It’s a fast track to being blacklisted.

“One of the most common reasons fundraises fail is the disconnect between a founder’s excitement about their tech—and what investors actually care about.”

What Investors Want to See in 2025

The bar has risen.

🔹 First-in-human isn’t enough
Where VCs used to back pre-clinical companies, many now want proof: clinical data, recurring revenue, and de-risked pathways to market.

🔹 Commercial-ready leadership
Founders need to show they’re building a company—not just a device. This means recruiting experienced operators early.

🔹 A credible plan for the next raise
VCs are cautious. They want to know how far this round will take you, and what’s coming next.

Building a Winning Pitch Deck and Data Room

Forget filler slides. According to Kiko, here’s what a world-class pitch includes:

✅ Clear clinical need
✅ Strong economic rationale (especially if you’re displacing legacy systems)
✅ Reimbursement pathway
✅ GTM (Go-to-Market) plan, tailored by geography
✅ Realistic deployment of funds—validated with hiring benchmarks

The data room? It’s more than a folder—it’s your first impression. Being able to respond quickly to investor requests matters as much as what’s in it.

“Investors aren’t just evaluating your tech. They’re evaluating you—how fast you respond, how you think, how prepared you are.”

Why (and When) to Use an Investment Bank

Hiring an investment advisor might seem like overkill, especially in early rounds. But Kiko made the case that founders are often too close to the story. A good advisor:

  • Helps craft a compelling equity narrative

  • Targets the right investors (and avoids the wrong ones)

  • Manages the time-drain of a raise so CEOs can stay focused on running the business

Kiko puts it simply:

“Fundraising is a full-time job. We lighten the load and bring structure, discipline, and reach.”

What Gets VCs Excited in 2025

Despite tough conditions, capital is still flowing—into the right areas.

🔹 Neurostimulation – Massive potential, early innings
🔹 Digital surgery and soft tissue robotics – Still evolving, especially with software integration
🔹 AI in imaging – Crowded, but high ceiling if reimbursement and economics align
🔹 Large, scalable markets – Cardiology, spine, and new frontiers in women’s health

And while Neuralink gets the headlines, Kiko believes the real opportunity may lie in the ecosystem around these breakthrough devices—training tools, supportive software, adjacent enabling tech.


MedTech M&A: How to Make Yourself Acquirable

If fundraising is a marathon, M&A is the finish line. Kiko shared what makes a startup attractive to strategics:

  • Recurring revenue and reference clients

  • Regulatory approvals and reimbursement in place

  • Fit with the acquirer’s portfolio and sales force

  • Scalable, de-risked operations

Crucially, M&A conversations should start years before a deal.

“The best exits are years in the making. It’s about relationships, not transactions.”


The Cruxx + Apparius Partnership: Talent Meets Capital

At Cruxx, we specialise in solving two of the biggest challenges in MedTech:
🔹 Executive talent
🔹 Access to capital

Our partnership with Apparius means we help our clients build the right teams and raise the right funding—with joined-up thinking from the start.

Whether it’s building a budget model with realistic hiring assumptions or co-pitching to VCs with aligned messaging, this partnership has helped companies win.

“We think like medtech nerds. But we act like your strategic partners.”


LISTEN ON YOUR FAVOURITE PODCAST PLATFORM
SpotifyApple podcastsAmazon music

More episodes in this industry

What's the Hype with Neuro? A Lesson in the Brain - With Hannah Claridge
Podcast43

What's the Hype with Neuro? A Lesson in the Brain - With Hannah Claridge

In this episode, your host, Henry Norton, is joined by Hannah Claridge, the Head of Neurotechnology at TTP, to talk about the incredible advancements that are being made to treat neurological conditions. Hannah points out how complex the brain and nervous systems are, with both relying on intricate connections. She also explores the new technologies that are being developed to treat nervous disorders, such as spinal cord stimulation. She also compared neurotechnologies to pharmaceuticals, highlighting the parallels and differences in how they interact with the body. Hannah also suggested that neurotherapy will be key to the advancement of treatments for conditions like depression, due to their ability to provide targeted and long-term relief of symptoms. Cybersecurity is also a major concern for neurotechnology, as any malfunction or deliberate interference could have serious ramifications for patients.
Why Most Medtech Fundraisers Fail and What to Do Instead - Kiko Filipov, Partner at APPARIUS
Podcast42

Why Most Medtech Fundraisers Fail and What to Do Instead - Kiko Filipov, Partner at APPARIUS

Raising capital in Medtech is tougher than ever. Investor expectations have shifted. Competition is up. And many founders are still pitching like it’s 2018. In this episode, Henry Norton sits down with Kiko Filipov, Partner at APPARIUS Corporate Finance and Strategic Advisor at Cruxx, to unpack the real mechanics of a successful fundraise in 2025. From first-in-human data to commercial readiness, Kiko shares what separates the rounds that get oversubscribed from the ones that stall. He also explores the changing landscape of Medtech innovation and why strategic exits take years of planning, how emerging markets are joining the race, and where VCs are placing bets across surgical robotics, neurostimulation, and digital health. Whether you're gearing up for Series A or preparing your pitch deck, this episode delivers tactical clarity from someone who’s in the room with both founders and funds.

Discover more about Medical Devices